1,287 reports of this reaction
1.6% of all LATANOPROST reports
#18 most reported adverse reaction
OCULAR HYPERAEMIA is the #18 most commonly reported adverse reaction for LATANOPROST, manufactured by Viatris Specialty LLC. There are 1,287 FDA adverse event reports linking LATANOPROST to OCULAR HYPERAEMIA. This represents approximately 1.6% of all 81,937 adverse event reports for this drug.
Patients taking LATANOPROST who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is a less commonly reported adverse event for LATANOPROST, but still significant enough to appear in the safety profile.
In addition to ocular hyperaemia, the following adverse reactions have been reported for LATANOPROST:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 1,287 FDA reports for LATANOPROST. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 1.6% of all adverse event reports for LATANOPROST, making it a notable side effect.
If you experience ocular hyperaemia while taking LATANOPROST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.